| dbo:abstract
|
- Femarelle is a dietary supplement that is a mixture of DT56a (a tofu extract) and flaxseed powder, that may act as a selective estrogen receptor modulator (SERM). In 2008 an application was submitted to the European Food Safety Authority to market Femarelle with a health claim, namely that it can reduce the risk for osteoporosis and other bone disorders; the EFSA found that "the food/constituent for which the claim is made, i.e. Femarelle, has not been sufficiently characterised" and that " a cause and effect relationship has not been established between the consumption of Femarelle and increased BMD, increased bone formation, or decreased risk of osteoporosis or other bone disorders in post-menopausal women." Femarelle has been tested in small clinical trials. One studied its effect on the tissue lining the vagina, another on relief of hot flashes in menopause, and another on the risk of causing blood clots, which is a risk of hormone replacement therapy. While results were promising, the studies were too small and too short in duration from which to draw conclusions. (en)
- DT56a (Femarelle) es un modulador selectivo de los receptores estrogénicos, MSRE, para el tratamiento de menopausia y salud ósea. El DT56a se obtiene a través de un proceso único de elaboración de las semillas de soja que produce un compuesto estable y estandarizado con características peculiares. (es)
- DT56a est un extrait de haricots de soja fermentés issu du tofu et de graines de lin ; il est qualifié de « mixture de phytoestrogènes » ou « phyto-modulateur sélectif des récepteurs aux œstrogènes (SERM) ». Ce complément alimentaire est commercialisé sous différentes marques et revendique des effets en matière de traitement de la ménopause et pour favoriser la santé osseuse, effets qui n'ont pas été validés par l'Autorité européenne de sécurité des aliments (AESA). (fr)
- 페마렐(femarelle, DT56a)은 선택적 에스트로겐 수용체 조절자(SERM, selective estrogen receptor modulator)로서 폐경증세와 골다공증에 쓰이는 약물이다. 페마렐은 대략 322 mg의 DT56a(두부 추출물)과 108 mg의 아마씨 가루를 함유하고 있다. (ko)
- Femarelle, também conhecido por Tofupill e Bonfemi, é um fármaco modulador seletivo do receptor de estrógeno (SERM) e usado para o tratamento da menopausa e saúde óssea. Trata-se de uma associação medicamentosa composta por DT56a (um extrato de grãos de soja) e linhaça em pó. (pt)
|
| dbo:thumbnail
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 2666 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- DT56a (Femarelle) es un modulador selectivo de los receptores estrogénicos, MSRE, para el tratamiento de menopausia y salud ósea. El DT56a se obtiene a través de un proceso único de elaboración de las semillas de soja que produce un compuesto estable y estandarizado con características peculiares. (es)
- DT56a est un extrait de haricots de soja fermentés issu du tofu et de graines de lin ; il est qualifié de « mixture de phytoestrogènes » ou « phyto-modulateur sélectif des récepteurs aux œstrogènes (SERM) ». Ce complément alimentaire est commercialisé sous différentes marques et revendique des effets en matière de traitement de la ménopause et pour favoriser la santé osseuse, effets qui n'ont pas été validés par l'Autorité européenne de sécurité des aliments (AESA). (fr)
- 페마렐(femarelle, DT56a)은 선택적 에스트로겐 수용체 조절자(SERM, selective estrogen receptor modulator)로서 폐경증세와 골다공증에 쓰이는 약물이다. 페마렐은 대략 322 mg의 DT56a(두부 추출물)과 108 mg의 아마씨 가루를 함유하고 있다. (ko)
- Femarelle, também conhecido por Tofupill e Bonfemi, é um fármaco modulador seletivo do receptor de estrógeno (SERM) e usado para o tratamento da menopausa e saúde óssea. Trata-se de uma associação medicamentosa composta por DT56a (um extrato de grãos de soja) e linhaça em pó. (pt)
- Femarelle is a dietary supplement that is a mixture of DT56a (a tofu extract) and flaxseed powder, that may act as a selective estrogen receptor modulator (SERM). In 2008 an application was submitted to the European Food Safety Authority to market Femarelle with a health claim, namely that it can reduce the risk for osteoporosis and other bone disorders; the EFSA found that "the food/constituent for which the claim is made, i.e. Femarelle, has not been sufficiently characterised" and that " a cause and effect relationship has not been established between the consumption of Femarelle and increased BMD, increased bone formation, or decreased risk of osteoporosis or other bone disorders in post-menopausal women." (en)
|
| rdfs:label
|
- DT56a (es)
- DT56a (fr)
- Femarelle (en)
- 페마렐 (ko)
- Femarelle (pt)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
